1. Generic Drugs - Market Overview
2. Executive Summary 
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Generic Drugs - Market Forces
4.1. Drivers
4.1.1. cost-effectiveness of generic drugs against branded drugs
4.2. Restraints
4.3. Opportunities
4.4. Challenges
4.5. Porter's Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Generic Drugs - Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis 
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Generic Drugs Market, By Drug Class
6.1. Cardiovascular Products
6.2. Anti-Infective Drugs
6.3. Anti-Arthritis Drugs
6.4. Central Nervous System Drugs
6.5. Anti-Cancer Drugs
6.6. Respiratory Products
6.7. Others
7. Generic Drugs Market, By Geography
7.1. Europe
7.1.1. Germany
7.1.2. France
7.1.3. Italy
7.1.4. Spain
7.1.5. Russia
7.1.6. U.K.
7.1.7. Rest of Europe
7.2. Asia Pacific
7.2.1. China
7.2.2. India
7.2.3. Japan
7.2.4. South Korea
7.2.5. Rest of Asia-Pacific
7.3. North America 
7.3.1. U.S.
7.3.2. Canada
7.3.3. Mexico
7.4. Rest of the World (RoW)
7.4.1. Brazil
7.4.2. Rest of RoW
8. Generic Drugs - Market Entropy
8.1. Expansion
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply- Contract
9. Company Profiles (Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
9.1. WATSON PHARMACEUTICALS, INC.
9.2. TEVA PHARMACEUTICAL INDUSTRIES, LTD. 
9.3. SANDOZ INTERNATIONAL GMBH
9.4. RANBAXY LABORATORIES, LTD. 
9.5. PAR PHARMACEUTICAL, INC.
9.6. MYLAN INC. 
9.7. HOSPIRA, INC.
9.8. DR. REDDY'S LABORATORIES, LTD. 
9.9. APOTEX INC. 
9.10. ACTAVIS
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix
10.1. Abbreviations
10.2. Sources
10.3. Research Methodology
10.4. Expert Insight